NCT02709798CompletedPhase 4
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Shenfu Injection on Reperfusion Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Pilot Trial
Beijing Anzhen Hospital1 site in 1 country40 target enrollmentStarted: April 2016Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Infarct size
Study Overview
Brief Summary
The purpose of this study is to evaluate whether perioperative use of Shenfu Injection could reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac magnetic resonance imaging) in patients with STEMI after primary PCI
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 and <75 years;
- •First-time acute anterior STEMI;
- •The time from onset of ischemic symptom to the time of initial PCI balloon inflation ≤6 hours;
- •>0.1 mV ST segment elevation in at least two contiguous precordial leads according to electrocardiogram;
- •Scheduled for primary PCI;
- •The presence of left anterior descending branch (LAD) occlusion in proximal or middle segment with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram;
- •Written informed consent.
Exclusion Criteria
- •Hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis, or myocarditis;
- •Cardiogenic shock, severe ventricular arrhythmia, serious heart failure (Killip class III and above) or mechanical complications;
- •Patients after cardiopulmonary resuscitation (CPR) (including cardioversion);
- •Patients who have already received thrombolytic therapy;
- •Prior myocardial infarction or coronary artery bypass surgery;
- •Known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases;
- •Malignant tumor, lymphoma, HIV-positive, or hepatitis;
- •Uncontrolled hypertension (systolic BP >160 mm Hg or a diastolic BP >100 mmHg on at least two consecutive readings);
- •Patients with active bleeding, major surgery or trauma within 3 months and cerebrovascular accident within 6 months;
- •History of anemia (hemoglobin<90g/L) or thrombocytopenia (thrombocyte<90×109/L);
- •Multi-vessel disease with non-culprit vessel intervention;
- •Breastfeeding, pregnant, or potentially fertile women;
- •Patients who have known to be allergic to Shenfu Injection or its components or patients with serious adverse effect;
- •Patients with potential contraindication to CMR;
- •Participation in other clinical trial in recent 3 months;
- •Patients who cannot complete this trial or comply with the protocol.
Arms & Interventions
Shenfu Injection
Experimental
80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Intervention: Shenfu Injection (Drug)
5% Glucose Injection
Placebo Comparator
150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Intervention: 5% Glucose Injection (Drug)
Outcomes
Primary Outcomes
Infarct size
Time Frame: immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI, as well as 4±1days after PCI
Infarct size was assessed by measuring the area under the curve (AUC) of creatine kinase isoenzyme (CK-MB) within 72 hours after PCI and by performing cardiac magnetic resonance (CMR) imaging at 4±1days after PCI.
Secondary Outcomes
- Peak value of CK-MB and cTnI(72 hours after PCI)
- Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and Left ventricular ejection fraction (LVEF)(up to 28 days after PCI)
- ST segment resolution (%) according to ECG(up to 24 hours after PCI)
- AUC of cardiac troponin I (cTnI)(immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI)
- Main adverse cardiovascular and cerebrovascular events (MACCE, including death, non-fatal myocardial infarction, target vessel revascularization, stroke, new-onset severe heart failure, re-hospitalization for heart failure)(up to 28 days after PCI)
Investigators
Shao-Ping Nie
MD, PhD
Beijing Anzhen Hospital
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 4
Randomized Evaluation of Shenfu Injection to Reduce Myocardial InjuryMyocardial InfarctionNCT04493840Beijing Anzhen Hospital326
Completed
Not Applicable
Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal BlockOsteoarthritis, KneeNCT02680392McGill University Health Centre/Research Institute of the McGill University Health Centre40
Unknown
Phase 4
the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.Myocardial InfarctionNCT02158559Beijing Bozhiyin T&S Co., Ltd.180
Completed
Not Applicable
Effect of SVV-guided Fluid Therapy on Outcomes After Major Abdominal SurgeryGoal-directed Fluid TherapyNCT03940144Beijing Tongren Hospital110
Completed
Phase 4
Danhong Injection in the Treatment of Acute Ischemic StrokeAcute StrokeNCT01677208China Academy of Chinese Medical Sciences1,503